Evidence map›Paper›PMID 23308067›Full record

ArticlePLoS pathogens2012

Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein.

Daniel Sauter, Daniel Unterweger, Michael Vogl, Shariq M Usmani, Anke Heigele, Silvia F Kluge, Elisabeth Hermkes, Markus Moll, Edward Barker, Martine Peeters and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Daniel SauterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Daniel Unterweger
Michael Vogl
Shariq M Usmani
Anke Heigele
Silvia F Kluge
Elisabeth Hermkes
Markus Moll
Edward Barker
Martine Peeters
Gerald H Learn
Frederic Bibollet-Ruche
Joëlle V Fritz
Oliver T Fackler
Beatrice H Hahn
Frank Kirchhoff
Universität Ulm · DEUniversity of Pennsylvania · USHeidelberg University · DEInstitut de Recherche pour le Développement · FRKarolinska Institutet · SERush University Medical Center · USUniversity Hospital Heidelberg · DE

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
Molecular Epidemiology and Natural History of SIVcpzR01AI058715 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2004 to 2013
$6.1M
Natural SIV Reservoirs and Human Zoonotic RiskR37AI050529 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2008 to 2017
$5.7M
Vpu inhibits NK cell function through down regulation of NTB-AR01AI065361 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI BARKER, EDWARD · 2006 to 2016
$2.9M
The Role of Matrix Cofactors in SIVcpz ReplicationR21AI080364 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BIBOLLET-RUCHE, FREDERIC · 2008 to 2009
$388k
NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI058715NIAID NIH HHS R01 AI065361NIAID NIH HHS R21 AI080364NIAID NIH HHS R37 AI050529
6 · The paper itself

Abstract

HIV-1 groups M and N emerged within the last century following two independent cross-species transmissions of SIVcpz from chimpanzees to humans. In contrast to pandemic group M strains, HIV-1 group N viruses are exceedingly rare, with only about a dozen infections identified, all but one in individuals from Cameroon. Poor adaptation to the human host may be responsible for this limited spread of HIV-1 group N in the human population. Here, we analyzed the function of Vpu proteins from seven group N strains from Cameroon, the place where this zoonosis originally emerged. We found that these N-Vpus acquired four amino acid substitutions (E15A, V19A and IV25/26LL) in their transmembrane domain (TMD) that allow efficient interaction with human tetherin. However, despite these adaptive changes, most N-Vpus still antagonize human tetherin only poorly and fail to down-modulate CD4, the natural killer (NK) cell ligand NTB-A as well as the lipid-antigen presenting protein CD1d. These functional deficiencies were mapped to amino acid changes in the cytoplasmic domain that disrupt putative adaptor protein binding sites and an otherwise highly conserved ßTrCP-binding DSGxxS motif. As a consequence, N-Vpus exhibited aberrant intracellular localization and/or failed to recruit the ubiquitin-ligase complex to induce tetherin degradation. The only exception was the Vpu of a group N strain recently discovered in France, but originally acquired in Togo, which contained intact cytoplasmic motifs and counteracted tetherin as effectively as the Vpus of pandemic HIV-1 M strains. These results indicate that HIV-1 group N Vpu is under strong host-specific selection pressure and that the acquisition of effective tetherin antagonism may lead to the emergence of viral variants with increased transmission fitness.

Indexed as

Selection, GeneticAmino Acid SequenceAntigens, CDBinding SitesBlotting, WesternBone Marrow Stromal Antigen 2Cells, CulturedFlow CytometryGPI-Linked ProteinsHIV-1HIV InfectionsHuman Immunodeficiency Virus ProteinsHumansMolecular Sequence DataProtein Interaction Domains and MotifsSequence Homology, Amino AcidAntigens, CDBone Marrow Stromal Antigen 2BST2 protein, humanGPI-Linked ProteinsHuman Immunodeficiency Virus ProteinsViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1

Identifiers

PMID23308067
PMCPMC3534379
OpenAlexW2048566355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.